Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.39 |
| ▸ | CPB1 | P15086 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6152839 | 1.00 | MMP2 (0.49) | MMP2MMP9CPB2FOLH1TLR2 | |
| SCHEMBL1087101 | 0.82 | KMT2A (0.49) | MMP2MMP9C3AR1CA1CA2 | |
| SCHEMBL1086444 | 0.82 | KMT2A (0.49) | MMP2MMP9C3AR1CA1CA2 | |
| SCHEMBL29017599 | 0.77 | MMP2 (0.53) | MMP2MMP9CPB2FOLH1TLR2 | |
| SCHEMBL7226850 | 0.76 | MMP2 (0.50) | MMP2MMP9CPB2TLR2ANPEP | |
| SCHEMBL7226853 | 0.76 | MMP2 (0.50) | MMP2MMP9CPB2TLR2ANPEP | |
| SCHEMBL8645817 | 0.76 | MMP2 (0.47) | MMP2MMP9FOLH1TLR2CA1 | |
| SCHEMBL22657404 | 0.75 | MMP2 (0.52) | MMP2MMP9CPB2FOLH1TLR2 | |
| SCHEMBL19100379 | 0.75 | MMP2 (0.52) | MMP2MMP9CPB2FOLH1TLR2 | |
| SCHEMBL9725920 | 0.75 | MME (0.49) | MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135502-B1 | Colchinol derivatives as vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2006-11-14 | — | — | US | disclosed |
| US-20060128633-A1 | Colchinol derivatives as vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. | 2006-06-15 | — | — | US | disclosed |
| EP-1140745-B1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | ANGIOGENE PHARM LTD (GB) | 2003-10-22 | — | — | EP | disclosed |
| EP-1140745-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | Angiogene Pharmaceuticals Ltd (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040529-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128633-A1 | Colchinol derivatives as vascular damaging agents | NR1H3, NR1H2, NR1H4 | MMP2 4497/4885MMP9 3467/4885CPB2 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.